Farxiga data 'have the potential to transform the standard of care'

AstraZeneca’s (LSE: AZN) Farxiga (dapagliflozin) – on top of standard care – met a Phase III trial’s primary endpoint and reduced the composite of worsening renal function or risk of death in patients with chronic kidney disease (CKD) with or without type-2 diabetes (T2D).

The full results reported a 39% reduction in worsening of renal function or risk of cardiovascular or renal death, and highlight Farxiga as the first medicine to significantly prolong survival by 31% in this patient population.

Trial investigators from the DAPA-CKD study have said that the data have the potential to transform the standard of care for this patient population, which has a significant unmet need for new and improved treatment options.